MARKET

CRMD

CRMD

Cormedix
NASDAQ
7.10
-0.20
-2.74%
After Hours: 7.30 +0.2 +2.82% 19:57 08/12 EDT
OPEN
7.30
PREV CLOSE
7.30
HIGH
7.31
LOW
7.10
VOLUME
1.35M
TURNOVER
--
52 WEEK HIGH
14.96
52 WEEK LOW
6.13
MARKET CAP
557.01M
P/E (TTM)
3.362
1D
5D
1M
3M
1Y
5Y
1D
Humacyte, Inc. (HUMA) Reports Q2 Loss, Misses Revenue Estimates
NASDAQ · 19h ago
Weekly Report: what happened at CRMD last week (0803-0807)?
Weekly Report · 2d ago
Cormedix Wins Preliminary OK on Governance Settlement Reforms
TipRanks · 5d ago
U.S. District Court Granted Preliminary Approval Of CorMedix Derivative Settlement On July 24; Final Hearing Set For September 23
Benzinga · 5d ago
Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Lags Revenue Estimates
NASDAQ · 08/04 21:15
Weekly Report: what happened at CRMD last week (0727-0731)?
Weekly Report · 08/03 09:29
Top profitable small caps trading at bargain P/E multiples during Q2 earnings
Seeking Alpha · 07/27 13:09
Weekly Report: what happened at CRMD last week (0720-0724)?
Weekly Report · 07/27 09:30
More
About CRMD
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.

Webull offers CorMedix Inc stock information, including NASDAQ: CRMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRMD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRMD stock methods without spending real money on the virtual paper trading platform.